Developer docs
API playgroundTry for free, no card

Search company profiles

Genocea Biosciences

Full company profile

uuid0004s5v

Namestring
Genocea Biosciences
Websiteurl
genocea.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Genocea Biosciences was a Cambridge, Massachusetts-based biopharmaceutical company founded in 2006 that developed personalized cancer vaccines and immunotherapies built around its proprietary neoantigen discovery platform. The company's scientific premise involved identifying tumor-specific neoantigens capable of stimulating anti-tumor immune responses, with an emphasis on distinguishing true immunogenic antigens from inhibitory ones — a differentiator in the personalized cancer vaccine space. Genocea pursued indications in melanoma and other oncology settings, with potential combination use alongside immune checkpoint inhibitors. The company was listed on NASDAQ under the ticker GNCA and had assembled a leadership team spanning CEO, CFO, CBO, CSO, and CMO functions.

The company's go-to-market was characteristic of clinical-stage biotech: it generated no commercial product revenue, raised capital through repeated equity and debt financings (at least 16 documented rounds totaling several hundred million dollars between 2009 and 2020), and relied on backing from life sciences-specialist investors including Polaris Partners, Lux Capital, Johnson & Johnson Development Corporation, Bill & Melinda Gates Foundation, and Hercules Capital. Multiple funding rounds in 2018–2020 collectively exceeded $260 million and were used to extend clinical runway. The provided financial statements contain evident data-quality issues — figures in the trillions are implausible for a pre-commercial biotech — and should be treated as unreliable.

Multiple signals indicate the company has ceased active operations: the genocea.com domain has been repurposed for unrelated content, the only recent reference to Genocea in news sources is as a former employer, and no current operational, clinical pipeline, or financial disclosures are documented. The company therefore appears to have wound down rather than continuing as an active going concern, and any analysis of its forward trajectory should be interpreted in that light.

Short descriptiontext

Genocea Biosciences was a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company that developed personalized neoantigen cancer vaccines and immunotherapies, primarily targeting melanoma and other oncology indications. The company appears to have ceased active operations.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
personalized cancer vaccines, neoantigen immunotherapy, T-cell antigen profiling, immuno-oncology therapeutics, biopharmaceutical R&D
Industry3 codes
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Personalized Cancer Vaccines
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Genocea Biosciences is a biopharmaceutical company developing personalized cancer vaccines and neoantigen-based immunotherapies. The company leverages proprietary T-cell antigen profiling to identify patient-specific tumor neoantigens and design vaccines targeting melanoma and other cancers, with pipeline candidates intended to be used in combination with immune checkpoint inhibitors.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Personalized Cancer Vaccines (neoantigen-based pipeline)
CategoryPersonalized cancer immunotherapy
Description

Patient-specific cancer vaccines developed using Genocea's neoantigen identification platform, designed for patients with melanoma and other cancers and intended for use in combination with immune checkpoint inhibitors.

2T-Cell Antigen Profiling Platform
CategoryImmuno-oncology discovery platform
Description

Proprietary platform that profiles patient-specific T-cell responses to identify biologically relevant tumor neoantigens, including the ability to filter out inhibitory antigens, supporting the design of Genocea's personalized cancer vaccines.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Agenus is a clinical-stage immuno-oncology company with a broad portfolio including vaccine platforms and checkpoint combinations, providing a comparable but broader-incumbent reference point for Genocea's combinatorial immunotherapy strategy.

TypeDirect peer
Description

Neon Therapeutics developed personalized neoantigen vaccines and was acquired by BioNTech; remains a directly relevant historical and technological reference point for Genocea's neoantigen vaccine platform and commercial path.

TypeEmerging player
Description

VBI Vaccines develops immunotherapeutic vaccine candidates for oncology and infectious disease; its therapeutic cancer vaccine efforts make it an emerging peer with thematic and patient-population overlap with Genocea.

TypeDirect peer
Description

CureVac develops mRNA-based cancer vaccines and immunotherapies, overlapping with Genocea's neoantigen vaccine approach and targeting similar oncology indications as a direct personalized cancer vaccine peer.

TypeDirect peer
Description

Moderna is the leading mRNA-based personalized cancer vaccine developer with mRNA-4157, a neoantigen vaccine in late-stage development — the most direct technical and clinical competitor to Genocea's personalized neoantigen vaccine platform.

TypeBroad incumbent
Description

Merck's Keytruda franchise dominates the immune checkpoint inhibitor space that Genocea's combination therapy strategy depends on, making Merck a critical combination-therapy partner / competitor and a broad incumbent shaping the category.

TypeEmerging player
Description

Nouscom is a clinical-stage biotech developing viral vector-based personalized neoantigen cancer vaccines, an emerging peer using a different delivery modality to address the same personalized cancer immunotherapy niche as Genocea.

TypeDirect peer
Description

Gritstone bio is a clinical-stage biotechnology company developing neoantigen-based immunotherapies (e.g., GRANITE and SLATE programs), directly comparable in platform technology and disease focus to Genocea's personalized neoantigen vaccines.

9Transgene
TypeEmerging player
Description

Transgene develops therapeutic cancer vaccines and immunotherapies (including TG4050, a personalized neoantigen vaccine), positioning it as a comparable emerging player in personalized oncology vaccination with overlapping clinical ambition.

TypeDirect peer
Description

BioNTech develops individualized neoantigen therapy BNT122 (autogene cevumeran) across multiple solid tumor indications, making it a directly comparable personalized cancer vaccine peer with overlapping patient population and development strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genocea Biosciences

Personalized Cancer Vaccinesgenocea.com

Genocea Biosciences was a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company that developed personalized neoantigen cancer vaccines and immunotherapies, primarily targeting melanoma and other oncology indications. The company appears to have ceased active operations.

What Genocea Biosciences does

Genocea Biosciences was a Cambridge, Massachusetts-based biopharmaceutical company founded in 2006 that developed personalized cancer vaccines and immunotherapies built around its proprietary neoantigen discovery platform. The company's scientific premise involved identifying tumor-specific neoantigens capable of stimulating anti-tumor immune responses, with an emphasis on distinguishing true immunogenic antigens from inhibitory ones — a differentiator in the personalized cancer vaccine space. Genocea pursued indications in melanoma and other oncology settings, with potential combination use alongside immune checkpoint inhibitors. The company was listed on NASDAQ under the ticker GNCA and had assembled a leadership team spanning CEO, CFO, CBO, CSO, and CMO functions.

The company's go-to-market was characteristic of clinical-stage biotech: it generated no commercial product revenue, raised capital through repeated equity and debt financings (at least 16 documented rounds totaling several hundred million dollars between 2009 and 2020), and relied on backing from life sciences-specialist investors including Polaris Partners, Lux Capital, Johnson & Johnson Development Corporation, Bill & Melinda Gates Foundation, and Hercules Capital. Multiple funding rounds in 2018–2020 collectively exceeded $260 million and were used to extend clinical runway. The provided financial statements contain evident data-quality issues — figures in the trillions are implausible for a pre-commercial biotech — and should be treated as unreliable.

Multiple signals indicate the company has ceased active operations: the genocea.com domain has been repurposed for unrelated content, the only recent reference to Genocea in news sources is as a former employer, and no current operational, clinical pipeline, or financial disclosures are documented. The company therefore appears to have wound down rather than continuing as an active going concern, and any analysis of its forward trajectory should be interpreted in that light.

Genocea Biosciences firmographics

Firmographics
Name
Genocea Biosciences
Website
https://genocea.com
Company type
Private
Founded year
2006
Operating status
Closed
Headcount range
51–100 employees
Short description
Genocea Biosciences was a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company that developed personalized neoantigen cancer vaccines and immunotherapies, primarily targeting melanoma and other oncology indications. The company appears to have ceased active operations.
Ownership category
akta.pro rank

Genocea Biosciences industry classification

Industry
Product category
Personalized Cancer Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • Personalized cancer vaccines
  • Neoantigen immunotherapy
  • T-cell antigen profiling
  • Immuno-oncology therapeutics
  • Biopharmaceutical R&D

Where Genocea Biosciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Genocea Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Genocea Biosciences product offering

Product offering

Core offering

Genocea Biosciences is a biopharmaceutical company developing personalized cancer vaccines and neoantigen-based immunotherapies. The company leverages proprietary T-cell antigen profiling to identify patient-specific tumor neoantigens and design vaccines targeting melanoma and other cancers, with pipeline candidates intended to be used in combination with immune checkpoint inhibitors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Personalized Cancer Vaccines (neoantigen-based pipeline) Patient-specific cancer vaccines developed using Genocea's neoantigen identification platform, designed for patients with melanoma and other cancers and intended for use in combination with immune checkpoint inhibitors.
  • T-Cell Antigen Profiling Platform Proprietary platform that profiles patient-specific T-cell responses to identify biologically relevant tumor neoantigens, including the ability to filter out inhibitory antigens, supporting the design of Genocea's personalized cancer vaccines.

Companies that use Genocea Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Genocea Biosciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Genocea Biosciences partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Genocea Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Agenus: Agenus is a clinical-stage immuno-oncology company with a broad portfolio including vaccine platforms and checkpoint combinations, providing a comparable but broader-incumbent reference point for Genocea's combinatorial immunotherapy strategy.
  • Merck & Co. Merck's Keytruda franchise dominates the immune checkpoint inhibitor space that Genocea's combination therapy strategy depends on, making Merck a critical combination-therapy partner / competitor and a broad incumbent shaping the category.

Direct peers

  • Neon Therapeutics: Neon Therapeutics developed personalized neoantigen vaccines and was acquired by BioNTech; remains a directly relevant historical and technological reference point for Genocea's neoantigen vaccine platform and commercial path.
  • CureVac: CureVac develops mRNA-based cancer vaccines and immunotherapies, overlapping with Genocea's neoantigen vaccine approach and targeting similar oncology indications as a direct personalized cancer vaccine peer.
  • Moderna: Moderna is the leading mRNA-based personalized cancer vaccine developer with mRNA-4157, a neoantigen vaccine in late-stage development — the most direct technical and clinical competitor to Genocea's personalized neoantigen vaccine platform.
  • Gritstone bio: Gritstone bio is a clinical-stage biotechnology company developing neoantigen-based immunotherapies (e.g., GRANITE and SLATE programs), directly comparable in platform technology and disease focus to Genocea's personalized neoantigen vaccines.
  • BioNTech: BioNTech develops individualized neoantigen therapy BNT122 (autogene cevumeran) across multiple solid tumor indications, making it a directly comparable personalized cancer vaccine peer with overlapping patient population and development strategy.

Emerging players

  • VBI Vaccines: VBI Vaccines develops immunotherapeutic vaccine candidates for oncology and infectious disease; its therapeutic cancer vaccine efforts make it an emerging peer with thematic and patient-population overlap with Genocea.
  • Nouscom: Nouscom is a clinical-stage biotech developing viral vector-based personalized neoantigen cancer vaccines, an emerging peer using a different delivery modality to address the same personalized cancer immunotherapy niche as Genocea.
  • Transgene: Transgene develops therapeutic cancer vaccines and immunotherapies (including TG4050, a personalized neoantigen vaccine), positioning it as a comparable emerging player in personalized oncology vaccination with overlapping clinical ambition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Genocea Biosciences social profiles

Digital presence

Genocea Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genocea Biosciences leadership team

Management profile

Number of profiles

Profiles12 records

Genocea Biosciences funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genocea Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genocea Biosciences

What does Genocea Biosciences do?

Genocea Biosciences is a biopharmaceutical company developing personalized cancer vaccines and neoantigen-based immunotherapies. The company leverages proprietary T-cell antigen profiling to identify patient-specific tumor neoantigens and design vaccines targeting melanoma and other cancers, with pipeline candidates intended to be used in combination with immune checkpoint inhibitors.

Is Genocea Biosciences a public or private company?

Genocea Biosciences is a private company. It is classified as public and is currently closed.

When was Genocea Biosciences founded?

Genocea Biosciences was founded in 2006. It employs 51 to 100 people.

Where is Genocea Biosciences based?

Genocea Biosciences is headquartered in Cambridge, United States, in the North America region.

Who are Genocea Biosciences's main competitors?

Broad incumbents on record are Agenus and Merck & Co.. Direct peers are Neon Therapeutics, CureVac, Moderna, Gritstone bio and BioNTech. Emerging players are VBI Vaccines, Nouscom and Transgene.

Does Genocea Biosciences have an API?

No public API is recorded for Genocea Biosciences.

What industry is Genocea Biosciences in?

Genocea Biosciences's product category is Personalized Cancer Vaccines. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanAcadia Pharma adds finance veteran Poole to boardAcadia Pharmaceuticals appointed Jonathan M. Poole to its Board of Directors on March 3, 2026, as part of its strategic growth initiatives. Mr. Poole's experience includes leadership roles at Vertex Pharmaceuticals, Evelo Biosciences, and Genocea Biosciences, focusing on finance and global expansion. The company is developing therapies for neurological and rare diseases with an expanding pipeline.BenzingaThe Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO ConferenBiotech stocks advanced in the week ended May 27, though the sector has underperformed year-to-date. Notable developments include Genocea Biosciences shutting down operations amid a cash crunch and planning to delist from Nasdaq by June 2, Verrica Pharmaceuticals receiving an FDA rejection for its viral skin infection treatment candidate on its third attempt, and Catalyst Biosciences announcing a deal to sell its complement protease medicine portfolio to Vertex Pharmaceuticals. Key catalysts for the week of May 30-June 4 include Azurity Pharma/Eton's PDUFA decision for lamotrigine suspension to treat epilepsy and presentations at the ASCO and EULAR conferences.BenzingaGenocea Closes Shop, Delists From NASDAQGenocea Biosciences Inc.'s board has voted to wind down the company's operations and voluntarily delist from NASDAQ, filing Form 25 with the SEC by June 2. The decision comes after the company received a Nasdaq non-compliance notice and had already cut its workforce by approximately 65% while exploring strategic alternatives with an investment bank. The company's shares dropped 68% to $0.07 during premarket trading following the announcement.GlobeNewswireGenocea Initiates Restructuring and Announces Plan to Explore Strategic AlternativesGenocea Biosciences initiated a restructuring process and engaged advisors to explore strategic alternatives, including a sale, merger, or reverse merger. The company plans a roughly 65% workforce reduction in Q2 2022 and is reviewing its clinical programs.BioSpaceGenocea Biosciences to Host Investor WebinarGenocea Biosciences announced an investor webinar on April 8, 2022, to coincide with the AACR Annual Meeting. The presentation will cover TiTAN trial data for GEN-011 and successful production using the PLANET process. The webinar will be followed by a Q&A session.GlobeNewswireGenocea to Present at the 32nd Annual Oppenheimer Healthcare ConferenceGenocea Biosciences CEO Chip Clark will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on March 17th. The company is developing neoantigen immunotherapies, including a Phase 1/2a trial for GEN-011 and monitoring patients in a trial for GEN-009.BioSpaceJohn Lunger, of Adaptimmune, Joins Genocea Biosciences’ Board of DirectorsJohn Lunger, Chief Patient Supply Officer at Adaptimmune, joined Genocea Biosciences' board of directors. He will support scaling technical operations for reliable delivery of cell therapies. Genocea is conducting a Phase 1/2a trial for its adoptive T cell therapy GEN-011.GlobeNewswireGenocea to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGenocea Biosciences CEO Chip Clark will present a corporate overview at the 11th Annual SVB Leerink Global Healthcare Conference on February 17th. The company is developing neoantigen immunotherapies, including a Phase 1/2a trial for GEN-011 and monitoring patients in a trial for GEN-009.BioSpaceGenocea Biosciences Provides Corporate UpdateGenocea Biosciences entered an R&D collaboration and option agreement with Janssen Biotech to study neoantigen immunogenicity and Inhibigens in cancer vaccines. The company also reported progress on its GEN-011 TiTAN trial, with initial data expected in Q1-Q2 2022.